Last reviewed · How we verify
NCT00943462
Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme
trial testing External-beam radiation therapy in Astrocytoma, Grade IV. Withdrawn.
1 June 2011
Quick facts
| Lead sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 June 2009 |
| Primary completion | 1 June 2011 |
| Estimated completion | 1 June 2011 |
Drugs / interventions tested
- External-beam radiation therapy
- Temozolomide (temozolomide) — full drug profile →
Conditions studied
- Astrocytoma, Grade IV — all drugs for Astrocytoma, Grade IV →
- Giant Cell Glioblastoma — all drugs for Giant Cell Glioblastoma →
- Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Who can join
Adults 18 to 70, any sex, with Astrocytoma, Grade IV or Giant Cell Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Positron Emission Tomography-Computed Tomography (PET-CT) with injection of 18F-fluoroethylcholine (FEC) could be a useful tool in the evaluation and follow-up of patients who have been diagnosed with glioblastoma multiforme (GBM) and who are treated with radiotherapy and temozolomide by allowing, for example, the distinction of necrosis from tumour tissue. This tool could help the clinician in making therapeutic decisions for GBM patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00943462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Astrocytoma, Grade IV
Currently open trials in the same condition.
- NCT06614855 — A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant G · Phase 1 · active not recruiting
- NCT05789394 — Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in · Phase 1 · recruiting
- NCT05303519 — SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) · Phase 3 · recruiting
- NCT06118723 — The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) · recruiting
- NCT03861299 — The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. · NA · recruiting
Other Centre hospitalier de l'Université de Montréal (CHUM) trials
Trials by the same sponsor.
- NCT06735638 — Outside the Cage (OTC) Robotic Esophagectomy · Phase 1 · not yet recruiting
- NCT07533253 — Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions · NA · not yet recruiting
- NCT05225272 — Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery · not yet recruiting
- NCT07497061 — Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pull · NA · not yet recruiting
- NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00943462 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM)
- Last refreshed: 21 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00943462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing